Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2010 February;62(1) > Minerva Pediatrica 2010 February;62(1):71-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA PEDIATRICA

A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,764


eTOC

 

REVIEWS  


Minerva Pediatrica 2010 February;62(1):71-8

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Pediatric antifungal therapy. Part II: neonatal infections

Allen U., Richardson S., McGuire W., Bow E., Robinson J., Rotstein C., Doyle J., Davies D., Hui C., Le Saux N., Merchant P., Laverdiere M., Read S.

Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada


PDF  


The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.

top of page

Publication History

Cite this article as

Corresponding author e-mail

upton.allen@sickkids.ca